Filtered By:
Condition: Back Pain
Cancer: Brain Cancers
This page shows you your search results in order of date.
Order by Relevance | Date
Total 66 results found since Jan 2013.
A measurement for chronic pain is a scientific holy grail – and we’re getting closer | Abdul-Ghaaliq Lalkhen
People who have chronic pain without a visible injury are often not believed, but new research can help visualise that painMost people, including doctors, do not appreciate that the organ that produces pain is the brain. A broken bone, damaged tissue or a bleeding wound is often the focus, but the experience of pain is the sum total of more than just the physical injury – it is the result of information sent from our nerves being filtered through an individual’s unique psychological makeup, genetics, gender, beliefs, expectations, motivations and emotional context. Pain is therefore an individual experience, and often ...
Source: Guardian Unlimited Science - May 25, 2023 Category: Science Authors: Abdul-Ghaaliq Lalkhen Tags: Medical research Health Science Neuroscience UK news Stroke Cancer Back pain Diabetes Source Type: news
Why Acupuncture Is Going Mainstream in Medicine
When the opioid addiction crisis began to surge in the U.S. about a decade ago, Dr. Medhat Mikhael spent a lot of time talking to his patients about other ways to heal pain besides opioids, from other types of medications to alternative treatments.
As a pain management specialist at MemorialCare Orange Coast Medical Center in Fountain Valley, Calif., he didn’t anticipate leaving behind the short-term use of opioids altogether, since they work so well for post-surgical pain. But he wanted to recommend a remedy that was safer and still effective.
That turned out to be acupuncture.
“Like any treatment, acupuncture...
Source: TIME: Health - April 29, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate medicine Source Type: news
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Archives of Physical Medicine and Rehabilitation Supplements
The American Congress of Rehabilitation Medicine (ACRM) offers an opportunity for members to be the guest editor of a Supplement to its journal, the Archives of Physical Medicine and Rehabilitation (Archives). The goal of the ACRM supplements is to publish high quality scientific manuscripts, which are thematically organized and of interest to ACRM members and to the general readership of the Archives. We are interested in proposals in all fields of rehabilitation, but especially those of interest to the ACRM membership as indicated by the existence of special interest and networking groups for brain injury, spinal cord in...
Source: Archives of Physical Medicine and Rehabilitation - April 23, 2021 Category: Rehabilitation Tags: Organization News Source Type: research
Emerging Role of PD-1 in the Central Nervous System and Brain Diseases
AbstractProgrammed cell death protein 1 (PD-1) is an immune checkpoint modulator and a major target of immunotherapy as anti-PD-1 monoclonal antibodies have demonstrated remarkable efficacy in cancer treatment. Accumulating evidence suggests an important role of PD-1 in the central nervous system (CNS). PD-1 has been implicated in CNS disorders such as brain tumors, Alzheimer ’s disease, ischemic stroke, spinal cord injury, multiple sclerosis, cognitive function, and pain. PD-1 signaling suppresses the CNS immune responsevia resident microglia and infiltrating peripheral immune cells. Notably, PD-1 is also widely express...
Source: Neuroscience Bulletin - April 20, 2021 Category: Neuroscience Source Type: research
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Archives of Physical Medicine and Rehabilitation Supplements
The American Congress of Rehabilitation Medicine (ACRM) offers an opportunity for members to be the guest editor of a Supplement to its journal, the Archives of Physical Medicine and Rehabilitation (Archives). The goal of the ACRM supplements is to publish high quality scientific manuscripts, which are thematically organized and of interest to ACRM members and to the general readership of the Archives. We are interested in proposals in all fields of rehabilitation, but especially those of interest to the ACRM membership as indicated by the existence of special interest and networking groups for brain injury, spinal cord in...
Source: Archives of Physical Medicine and Rehabilitation - February 23, 2021 Category: Rehabilitation Tags: Organization News Source Type: research
